Why the TETON-PPF milestone matters for United Therapeutics stock

United Therapeutics (UTHR) has reached full enrollment in its 754 patient TETON-PPF phase 3 trial of nebulized Tyvaso for progressive pulmonary fibrosis, a key step toward potential label expansion.

This milestone gives you a clearer timetable for the next catalyst. Topline data are expected in the second half of 2027, and the company has flagged the study as a basis for a possible supplemental FDA filing.

United Therapeutics shares trade at US$508.48 after a 1-day share price return of 1.75%, while the 30-day share price return is down 5.08% and the 90-day share price return is down 10.29%. However, the 1-year total shareholder return of 61.88% shows that longer term momentum remains intact.

If this TETON-PPF milestone has you thinking about what else is moving in healthcare, it could be a useful moment to scan 40 healthcare AI stocks.

The recent pullback after a strong 1 year run leaves you weighing two views on United Therapeutics. Are you seeing a cooler market mood after good news, or a share price that has run ahead of fundamentals before TETON readouts and further valuation analysis?

Most Popular Narrative: 23.6% Undervalued

United Therapeutics is priced at $508.48 against a widely followed fair value narrative of $665.23, so the valuation debate now centers on what is being assumed in those long range cash flow and earnings forecasts.

The company's innovation wave pipeline including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing) positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

Want to see what revenue path and margin profile support that higher fair value for United Therapeutics? The narrative leans on detailed growth, profitability, and discount rate assumptions that many investors may not have fully stress tested yet.

Result: Fair Value of $665.23 (UNDERVALUED)

However, the United Therapeutics narrative could still be challenged if key trials like ADVANCE OUTCOMES disappoint, or if pricing pressure compresses those 41.1% margin assumptions.

Next Steps

Given the upbeat tone around United Therapeutics so far, it makes sense to move quickly and test the optimism against your own reading of the data in detail. A good place to start is by reviewing the 4 key rewards.

Looking for more United Therapeutics investment ideas?

If United Therapeutics is on your radar, this is the moment to widen your watchlist and uncover fresh ideas that match your risk, income, and value goals.

• Explore potential value by checking companies that screen as 53 high quality undervalued stocks.
• Consider income-focused opportunities by reviewing stocks highlighted as 10 dividend fortresses.
• Manage downside risk by looking at companies filtered as 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.